Whittier Trust Co. Invests $62,000 in Haemonetics Co. (NYSE:HAE)

Whittier Trust Co. purchased a new stake in Haemonetics Co. (NYSE:HAE) in the 4th quarter, HoldingsChannel reports. The institutional investor purchased 800 shares of the medical instruments supplier’s stock, valued at approximately $62,000.

A number of other large investors have also added to or reduced their stakes in the stock. Intech Investment Management LLC boosted its position in shares of Haemonetics by 62.9% during the 3rd quarter. Intech Investment Management LLC now owns 22,329 shares of the medical instruments supplier’s stock worth $1,795,000 after acquiring an additional 8,626 shares in the last quarter. Cerity Partners LLC boosted its holdings in shares of Haemonetics by 31.1% in the 3rd quarter. Cerity Partners LLC now owns 8,855 shares of the medical instruments supplier’s stock valued at $712,000 after purchasing an additional 2,102 shares in the last quarter. Loomis Sayles & Co. L P boosted its holdings in shares of Haemonetics by 8.1% in the 3rd quarter. Loomis Sayles & Co. L P now owns 163,856 shares of the medical instruments supplier’s stock valued at $13,171,000 after purchasing an additional 12,310 shares in the last quarter. FMR LLC increased its stake in shares of Haemonetics by 206.3% in the 3rd quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock valued at $62,257,000 after purchasing an additional 521,640 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of Haemonetics by 174.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier’s stock worth $1,362,000 after buying an additional 10,774 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on HAE. StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. Raymond James reiterated a “strong-buy” rating and set a $115.00 price objective (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Barrington Research cut their target price on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. JMP Securities decreased their target price on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research note on Friday, February 7th. Finally, JPMorgan Chase & Co. initiated coverage on Haemonetics in a research note on Friday, December 6th. They issued an “overweight” rating and a $116.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $101.22.

Haemonetics Trading Up 0.9 %

NYSE:HAE opened at $64.55 on Tuesday. Haemonetics Co. has a 52 week low of $58.80 and a 52 week high of $97.97. The firm’s fifty day moving average is $66.99 and its 200-day moving average is $74.96. The firm has a market cap of $3.24 billion, a P/E ratio of 25.41, a P/E/G ratio of 1.11 and a beta of 0.43. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Equities analysts expect that Haemonetics Co. will post 4.55 earnings per share for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.